Castle Biosciences (CSTL) Current Leases (2021 - 2026)

Castle Biosciences has reported Current Leases for 6 years, with the latest figure at $1.4 million in Q2 2026.

• Quarterly Current Leases fell 9.8% year-over-year to $1.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.4 million (down 9.8% YoY) and the FY2025 annual result came in at $1.3 million, down 20.42% from the prior year.
• Current Leases climbed to $1.4 million in Q2 2026 per CSTL's latest filing, from $1.3 million in the prior quarter.
• Over five years, Current Leases peaked at $2.0 million in Q2 2023 and troughed at $1.1 million in Q3 2023.
• A 5-year average of $1.4 million and a median of $1.4 million in 2025 frame the typical range for Current Leases.
• The sharpest annual moves came in 2023 and 2024: Current Leases surged 62.35% in 2023, then slumped 37.64% in 2024.
• Over 5 years, Current Leases stood at $1.8 million in 2022, then plunged by 36.02% to $1.1 million in 2023, then jumped by 46.44% to $1.7 million in 2024, then fell by 20.42% to $1.3 million in 2025, then advanced by 6.94% to $1.4 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $1.4 million, $1.3 million, and $1.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.